Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

MadeMed vs Nova MD

Two GLP-1 desks, one scoreboard. We put MadeMed and Nova MD head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 8 · Grade B

MadeMed

Visit MadeMed Full brief →
vs
No. 279 · Grade C

Nova MD

Visit Nova MD Full brief →

The verdict

MadeMed takes this head-to-head.

MadeMed scores 86 to 63 on our six-factor Brief Score — Publishes a price for every dose of every route — which makes it easy to brief, and expensive if you stay low.

That doesn't make Nova MD a bad call — it's best for readers who want lowest 3-month compounded pricing with an explicit microdose program. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
92
46
Supply Reliability
84
69
Transparency
94
72
Access Breadth
76
50
Clinical Oversight
84
83
Track Record
82
68
MadeMedBrief Score 86 · 63Nova MD

Price, coverage & the tracker

MadeMedNova MD
Brief Score86/100 (B)63/100 (C)
Semaglutide$239/mo injectable · $219/mo sublingual (quarterly)From $125/mo (3-month plan, compounded)
Tirzepatide$399/mo injectable · $299/mo sublingual (quarterly)From $199/mo (3-month plan, compounded)
Coverage40 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

MadeMed: Publishes one price per route that holds at every dose — the cleanest dose-to-price mapping we track.

Nova MD: New to the tracker on 1 August 2026. The published line reads From $125/mo (3-month plan, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.